Article

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

2024-04-19

Abstract excerpt

<h4>Background</h4> Early therapeutic intervention in high-risk SMM (HR-SMM) has demonstrated benefit in previous studies of lenalidomide with or without dexamethasone. Triplets and quadruplet studies have been examined in this same population. However, to date, none of these studies examined the impact of depth of response on long-term outcomes of participants treated with lenalidomide-based therapy, and whether...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f9fbee99-dc85-5b80-91b1-ef0d45491fc2
DOI: 10.1101/2024.04.19.24306082

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneDOI 10.1101/2024.04.19.24306082Read

Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering MyelomaSemantic proximity Read

Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.Semantic proximity Read

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.Semantic proximity Read

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaSemantic proximity Read

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaSemantic proximity Read

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple MyelomaSemantic proximity Read

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple MyelomaSemantic proximity Read

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.Semantic proximity Read

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.Semantic proximity Read

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patientsSemantic proximity Read